רווח נקי למניה (EPS TTM) Repligen Corporation (RGEN)
Repligen Corporation is developing advanced bioprocessing systems through large-scale R&D investments, utilizing external partners for the production of standard components while maintaining full control over patents. Revenue stability is based on consistent demand for consumables, as confirmed by GURU.Markets quotes that form this chart. A snapshot of the rolling annual earnings per share clearly demonstrates the business's resilience, where -0.21 serves as the final level mark.
RGEN (Repligen Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים
To find a balance between valuation and business quality, it is essential to evaluate the TTM EPS—the aggregate annual net income per share, which neutralizes the impact of share issuance on profitability. The trend of the rolling annual net income per share reflects the efficiency of Repligen Corporation (RGEN) engineering solutions in biopharmaceuticals, converting technological leadership into adjusted per-share income.
